Cure My Disease

Don't miss your cure!

 Log in / Sign up

A blood test and ultrasound could reveal hidden heart risk in young arthritis patients

NCT ID NCT07772466

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This study looks at whether two simple tests can spot early signs of heart disease in people under 50 who were recently diagnosed with rheumatoid arthritis (RA). The tests are a blood-based measure called the atherogenic index of plasma and an ultrasound of the neck arteries. The goal is to see if these markers can identify preclinical atherosclerosis, or artery hardening, before any symptoms appear. The study will compare RA patients with healthy volunteers of similar age and sex.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better early detection of heart disease risk in young rheumatoid arthritis patients, potentially guiding preventive care.
What could go wrong
This is an observational study with a small number of participants, so results may not apply broadly. It measures risk markers, not actual heart events, so the link to future disease is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

adult patients presented to rheumatology department with early rheumatoid arthritis

Ages

18 to 50 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: for cases (Rheumatoid Arthritis patients) * Patients fulfilling the 2010 American College of Rheumatology / European League Against Rheumatism (ACR/EULAR) classification criteria for RA * Disease duration of ≤6 months from the onset of symptoms (early RA) For Controls (Healthy Subjects): * Healthy volunteers aged 18 to 49 years with no known inflammatory, autoimmune, or chronic disease. * Age- and sex-matched (within ±2 years) to case subjects Exclusion Criteria: * Established cardiovascular disease (coronary artery disease, prior myocardial infarction, stroke, peripheral arterial disease, or heart failure). * Diabetes mellitus, Hypertension, and Dyslipidaemia on lipid-lowering therapy (statins, fibrates, niacin, or omega-3 agents), as these agents directly modify AIP values. * Chronic kidney disease (eGFR \<60 mL/min/1.73 m²) and Hepatic disease, thyroid dysfunction, or any other significant endocrine disorder. * Pregnancy or lactation. * Other connective tissue diseases (systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome). * Other inflammatory arthropathies (psoriatic arthritis, ankylosing spondylitis, reactive arthritis).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atheroscleroses are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerosis rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atheroscleroses Rheumatoid arthritis (RA)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.